CEL-SCI reports June patient enrollment in its phase 3 head and neck cancer trial
CEL-SCI announced that in June it has enrolled 25 patients in its ongoing Phase 3 trial of its investigational immunotherapy Multikine in just diagnosed, not yet treated patients with head and neck cancer. Total patient enrollment is the world's largest Phase 3 study in head and neck cancer. July 01, 2015